Focused On-demand Library for Small ribosomal subunit protein uS2m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y399

UPID:

RT02_HUMAN

Alternative names:

28S ribosomal protein S2, mitochondrial

Alternative UPACC:

Q9Y399; Q5T899; Q9BSQ4

Background:

Small ribosomal subunit protein uS2m, also known as 28S ribosomal protein S2, mitochondrial, plays a crucial role in mitoribosome formation, stability, and mitochondrial translation. This protein's involvement in these processes is essential for the proper functioning of mitochondria, the powerhouse of the cell.

Therapeutic significance:

Combined oxidative phosphorylation deficiency 36, a disease linked to mutations in the gene encoding Small ribosomal subunit protein uS2m, highlights the protein's critical role in mitochondrial health. Understanding the role of Small ribosomal subunit protein uS2m could open doors to potential therapeutic strategies.